Metabolic medicines
Levothyroxine (T4)
Synthetic T4 replaces thyroid deficiency; correcting a mildly high TSH does not always improve symptoms.
Large subclinical-hypothyroidism trial and replacement comparisons
Also known as: T4
Practical use
Applying the explained evidence
- Where it fits
- Synthetic T4 replaces thyroid deficiency; correcting a mildly high TSH does not always improve symptoms.
- Put the information into practice
- Overt deficiency, subclinical hypothyroidism and normal thyroid function are different populations. A negative trial in one group does not mean replacement is unnecessary in another, nor that everyone with fatigue benefits.
- The outcome being treated
- Identify whether the evidence concerns a diagnosed condition, body weight, appetite or a laboratory marker. Check which outcomes were measured and over what follow-up before transferring a finding to another goal.
- Keep this limit in view
- In TRUST, substantial biochemical separation did not produce a meaningful average tiredness benefit.
Overview
Levothyroxine is synthetic thyroxine, or T4, which tissues convert to T3. Synthroid is approved for hypothyroidism and selected thyroid-cancer TSH suppression. A boxed warning states it is not a treatment for obesity or weight loss.
Risks and limitations
Over-replacement can produce arrhythmia, angina, tremor, insomnia and reduced bone density. Adrenal insufficiency must be addressed. Absorption is affected by iron, calcium and other medicines; diabetes and anticoagulant treatment may be affected. Serious cardiac symptoms need medical attention.
How to read this
Overt deficiency, subclinical hypothyroidism and normal thyroid function are different populations. A negative trial in one group does not mean replacement is unnecessary in another, nor that everyone with fatigue benefits.
Research explained
TRUST: biochemical change without symptom benefit
Who was studied
737 adults aged at least 65 with persistent subclinical hypothyroidism and normal free T4; placebo-controlled, one-year primary outcomes.
- TSH at one year: levothyroxine
- 3.63 mIU/L
- TSH at one year: placebo
- 5.48 mIU/L
What was found
Mean TSH fell from 6.40 mIU/L at baseline to 3.63 with levothyroxine versus 5.48 with placebo. The between-group symptom-score difference was 0.0 points (95% CI−2.0 to 2.1); tiredness difference was 0.4 points (−2.1 to 2.9). The predefined clinically important difference was 9 points.
What it cannot establish
Applies to this older, mainly mildly affected subclinical population. It does not test withholding replacement in overt hypothyroidism or predict results in young adults.
Read the original studyT4 versus alternative replacement strategies
Who was studied
75 hypothyroid patients in a randomized blinded crossover trial using three 22-week treatment periods.
What was found
The full sample had broadly similar symptom and cognitive outcomes across T4, combined T4/T3 and desiccated extract; a symptomatic subgroup differed.
What it cannot establish
Small, selected treated population; does not prove one approach is best for every individual.
Read the original studyWhy response takes time
T4 has a multiday half-life, and labeling notes that full effect can take several weeks. Day-to-day weight or energy changes cannot establish that a stable thyroid response has been reached.
Supporting sourceA laboratory target is not the only endpoint
Lower TSH did not produce a meaningful average improvement in tiredness. A laboratory change and clinical benefit are different endpoints.
Supporting sourceAvoid overgeneralizing the negative result
Participants had normal free T4. This result cannot be generalized to untreated overt hormone deficiency.
Supporting sourceAbsorption and interpretation
Food, supplements and medicines can change exposure; biotin can interfere with some thyroid tests. A result requires context rather than an automatic conclusion that more hormone is needed.
Supporting sourceWhat physique expectations remain unknown
Neither trial studied fat-loss regimens in euthyroid bodybuilders. There is no supported gain-to-risk ratio or predictable retained-muscle result to attach to this use.
Supporting sourceClaims versus findings
Not established
Bringing any high TSH down necessarily fixes fatigue.
In TRUST, substantial biochemical separation did not produce a meaningful average tiredness benefit.
Check the evidenceCommon questions
Does the TRUST trial show thyroid medicine never works?
No. It addresses older adults with subclinical disease, not every cause or severity of hypothyroidism.
SourceSources
Synthroid prescribing information
Replacement treatment crossover trial
Sources checked 2026-09-28.
General education; not a personal treatment plan.